76 related articles for article (PubMed ID: 18939498)
1. [Current status of HIV vaccine development].
Seki S; Matano T
Nihon Rinsho; 2008 Oct; 66(10):1965-9. PubMed ID: 18939498
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
[TBL] [Abstract][Full Text] [Related]
3. HIV CTL escape: at what cost?
Smith SM
Retrovirology; 2004 May; 1():8. PubMed ID: 15169568
[TBL] [Abstract][Full Text] [Related]
4. Reversion of CTL escape-variant immunodeficiency viruses in vivo.
Friedrich TC; Dodds EJ; Yant LJ; Vojnov L; Rudersdorf R; Cullen C; Evans DT; Desrosiers RC; Mothé BR; Sidney J; Sette A; Kunstman K; Wolinsky S; Piatak M; Lifson J; Hughes AL; Wilson N; O'Connor DH; Watkins DI
Nat Med; 2004 Mar; 10(3):275-81. PubMed ID: 14966520
[TBL] [Abstract][Full Text] [Related]
5. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
[TBL] [Abstract][Full Text] [Related]
6. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
[TBL] [Abstract][Full Text] [Related]
7. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
8. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
Belyakov IM; Ahlers JD
Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
[TBL] [Abstract][Full Text] [Related]
9. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
10. HIV and SIV CTL escape: implications for vaccine design.
Goulder PJ; Watkins DI
Nat Rev Immunol; 2004 Aug; 4(8):630-40. PubMed ID: 15286729
[No Abstract] [Full Text] [Related]
11. Rates of HIV immune escape and reversion: implications for vaccination.
Davenport MP; Loh L; Petravic J; Kent SJ
Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
[TBL] [Abstract][Full Text] [Related]
12. Development of prophylactic AIDS vaccines: the current state of affairs.
Hanke T
Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.
Price DA; O'callaghan CA; Whelan JA; Easterbrook PJ; Phillips RE
Clin Sci (Lond); 1999 Dec; 97(6):707-18. PubMed ID: 10585898
[TBL] [Abstract][Full Text] [Related]
14. [HIV vaccine].
Matano T
Nihon Rinsho; 2005 May; 63 Suppl 5():659-65. PubMed ID: 15954426
[No Abstract] [Full Text] [Related]
15. A condition for successful escape of a mutant after primary HIV infection.
Monteiro LH; Gonçalves CH; Piqueira JR
J Theor Biol; 2000 Apr; 203(4):399-406. PubMed ID: 10736216
[TBL] [Abstract][Full Text] [Related]
16. [Development of an AIDS vaccine: status report].
Girard MP
Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
[TBL] [Abstract][Full Text] [Related]
17. Correlates of cytotoxic T-lymphocyte-mediated virus control: implications for immunosuppressive infections and their treatment.
Wodarz D; Nowak MA
Philos Trans R Soc Lond B Biol Sci; 2000 Aug; 355(1400):1059-70. PubMed ID: 11186307
[TBL] [Abstract][Full Text] [Related]
18. No vaccine against HIV yet--are we not perfectly equipped?
Singh M
Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
[TBL] [Abstract][Full Text] [Related]
19. Current strategies and limitations of HIV vaccines.
Kawalekar OU; Shedlock DJ; Weiner DB
Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV adaptive immunity: determinants for viral persistence.
Yamamoto H; Matano T
Rev Med Virol; 2008; 18(5):293-303. PubMed ID: 18416450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
